GO
Loading...

Pharmaceuticals

More

  • What Went Right in 2007 Thursday, 3 Jan 2008 | 11:05 AM ET

    Cramer reviews his top picks of the year and the lessons he learned from their success.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Dendreon And Desmond: Flippin' Through The LA Times Wednesday, 2 Jan 2008 | 1:36 PM ET

    The "Dendreonians" have probably already seen it, but I wanted to call your attention to a pretty long piece that ran in the health section of the Los Angeles Times on Dec. 31st. It's about the grass-roots movement to get Dendreon's prostate cancer drug, Provenge, approved by the FDA. Here's the link.

  • AstraZeneca Seeks Seroquel XR Approval Extension Wednesday, 2 Jan 2008 | 8:52 AM ET

    AstraZeneca said on Wednesday it was seeking approval from U.S. regulators to sell an extended-release version of its Seroquel drug to treat both manic and depressive episodes associated with bipolar disorder.

  • My 7 For '07: The Pharma Year in Review Friday, 28 Dec 2007 | 1:57 PM ET

    The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.

  • Glaxo's Avandia Scare: Market Feels Effects Thursday, 27 Dec 2007 | 10:46 AM ET

    A Merrill Lynch research note to clients titled, "Diabetics scared off therapy," contains some interesting observations about what's happened to the oral diabetes drug market in the wake of the Avandia safety scare earlier this year.

  • Wyeth: More Heartburn From Copycats? Wednesday, 26 Dec 2007 | 11:41 AM ET

    Shares of drugmaker Wyeth could remain under pressure this day after Christmas. At least two analysts are suggesting that Wyeth could be under assault by another generic drug company.

  • Genentech Won't Let Up on Lucentis Monday, 24 Dec 2007 | 12:01 PM ET

    Yes, I'd rather be blogging about another topic by now, but I hope this will be the last entry -- at least for awhile -- on the Avastin vs. Lucentis story. You see, last Friday I got repeatedly voice-mailed and e-mailed by Christine Castro, the new head of corporate communications/media relations at Genentech...

  • Wyeth Sues Teva over Heartburn Drug Patent Monday, 24 Dec 2007 | 7:36 AM ET

    Wyeth said Monday it will sue Teva Pharmaceuticals USA for alleged patent infringement and said it received an approvable letter from U.S regulators for bazedoxifene, a drug that helps prevent post-menopausal osteoporosis.

  • Did Genentech Back Down or Backpedal? Friday, 21 Dec 2007 | 12:11 PM ET

    So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.

  • On the Line: Rite Aid CEO Mary Sammons Thursday, 20 Dec 2007 | 7:48 PM ET

    The stock was crushed Thursday after reporting bad numbers. But Sammons is urging investors to stay for the long haul.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • On the Line: Medco CEO David Snow Thursday, 20 Dec 2007 | 7:47 PM ET

    Cramer knew the company had great earnings visibility, but the chief executive says it's better than the Mad Money host thought.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Genentech, Doctors Now See "Eye To Eye" On Avastin Thursday, 20 Dec 2007 | 4:35 PM ET

    Genentech today has essentially backed down from a proposed crackdown on doctors' use of the cancer drug Avastin instead of the way more expensive Lucentis. The drugs are used to treat age-related macular degeneration (AMD, for short), which is the leading cause of blindness in adults.

  • Masters of Execution: CVS Caremark Wednesday, 19 Dec 2007 | 7:26 PM ET

    This pharmacy used to be number two in the sector. But a smart acquisition helped it take the lead. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Most of my PR and professional contacts send Christmas cards, but for the past two years the boutique Wall Street firm, Rodman & Renshaw, has sent me heavy metal piggy banks. I assume the company sends them to its clients as well.

  • On the Line: BioMarin CEO Jean-Jacques Bienaime Tuesday, 18 Dec 2007 | 12:27 PM ET

    FDA approval for a key drug is making this company some mad money.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Medco Has Long, Healthy Life Ahead Tuesday, 18 Dec 2007 | 12:09 PM ET

    Thanks to some key drugs coming off patent, this pharmacy benefits manager could make $6 billion over the next five years.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Eli Lilly

    Eli Lilly announced this morning that Chairman and CEO Sidney Taurel is retiring as CEO on March 31st next year. He will stay on as Chairman and on April Fool's Day Chief Operating Officer John Lechleiter will take over as CEO. Investors, at least in early trading, seem to like the choice.

  • Japan to Cut Drug Prices by 5.2% in 2008: Source Tuesday, 18 Dec 2007 | 4:06 AM ET

    Japan will order an average drug price cut of 5.2 percent in its latest drug price review to take effect from next April, a government source said on Tuesday.

  • Heart Disease Still the Leading Cause of Death in US Monday, 17 Dec 2007 | 6:44 PM ET

    The number of Americans dying from cardiovascular disease is going down, but it's still the leading cause of death in the United States. The American Heart Association reports that in 2004 -- the most recent year statistics that are available -- 42,000 fewer people died from cardiovascular disease than in 2003.

  • Cancer Study Shows Over 7.5 Million Deaths in 2007 Monday, 17 Dec 2007 | 1:20 PM ET

    More than seven-and-a-half million people -- or about 20,000 people a day -- will die of cancer this 2007.  That's the sobering new estimate from a first-of-its-kind global study out of the American Cancer Society.